Since Bcl-2 inhibition and mTORC 1/2 inhibition are synergistic for cancer treatment, we investigated ABT-263 alone and in combination with an mTORC 1/2 inhibitor, TAK-228 (sapanisertib).35 This evidence concerns the gene BCL2 and cancer.